NOCOPI TECHNOLOGIES INC/MD/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NOCOPI TECHNOLOGIES INC/MD/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.12M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.08M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $4.63M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $1.95M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.66M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $2.54M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $3.34M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.57M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $1.38M | Mar 29, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $813.4K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.10M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.10M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $3.90M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $1.21M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.54M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.70M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $2.78M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.12M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $941.4K | Mar 29, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($154.9K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.68M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.44M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.81M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $49.4K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $508.4K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $754.9K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.66M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $381.2K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $258.5K | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($601.4K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.30M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.87M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $2.05M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $25.2K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $479.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $806.3K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.87M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $406.3K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $271.8K | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $179.9K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $178.2K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $163.4K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $140.4K | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $181.5K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $173.5K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $165.6K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $153.2K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $146.3K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $138.8K | Mar 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $713.9K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $594.8K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($19.3K) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($43.3K) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $512.7K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $702.4K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $360.6K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $40.9K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $177.5K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $202.6K | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.9K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $28.5K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $800 | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $31.6K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $38.6K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $73.4K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $500 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $6.6K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $1.4K | Mar 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.04M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $13.92M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $14.00M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $9.62M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $3.79M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.87M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $3.53M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $2.52M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $812.5K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $558.0K | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $281.6K | Mar 25, 2025 |
| FY2024 | Dec 31, 2023 | $1.62M | Mar 25, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.60M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $13.64M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $12.38M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $8.82M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | $3.51M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | $3.45M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $2.79M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $1.97M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $215.2K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($179.6K) | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.20M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($12.05M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($9.37M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($7.93M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($9.75M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($9.80M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($10.30M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($11.06M) | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | ($12.81M) | Mar 30, 2020 |
| FY2017 | Dec 31, 2016 | ($13.19M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.55M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $10.84M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.27M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $917.4K | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $1.85M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.36M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $688.0K | Mar 30, 2021 |
| FY2020 | Dec 31, 2018 | $400.8K | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $360.4K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $199.1K | Mar 29, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.84M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 10.79M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 10.50M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 9.25M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 6.75M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 67.35M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 61.04M | Mar 30, 2021 |
| FY2020 | Dec 31, 2018 | 58.62M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | 58.62M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | 58.60M | Mar 29, 2019 |